Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 0% Improvement Relative Risk Ventilation 50% ICU admission -50% Hospitalization time 11% Sedighi et al. Fluvoxamine for COVID-19 RCT LATE Is late treatment with fluvoxamine beneficial for COVID-19? Double-blind RCT 72 patients in Iran Trial underpowered to detect differences Sedighi et al., Neuropsychopharmacology Reports, doi:10.1002/npr2.12327 Favors fluvoxamine Favors control

Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non‐critical COVID‐19 pneumonia: A double‐blind randomized, placebo‐controlled clinical trial

Sedighi et al., Neuropsychopharmacology Reports, doi:10.1002/npr2.12327
Sedighi et al., Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non‐critical.., Neuropsychopharmacology Reports, doi:10.1002/npr2.12327
Mar 2023   Source   PDF  
  All Studies   Meta
RCT 72 patients in Iran, showing faster reduction of inflammation with treatment. There was no significant difference in mortality, ventilation, or ICU admission (few events).
risk of death, no change, RR 1.00, p = 1.00, treatment 1 of 36 (2.8%), control 1 of 36 (2.8%).
risk of mechanical ventilation, 50.0% lower, RR 0.50, p = 1.00, treatment 1 of 36 (2.8%), control 2 of 36 (5.6%), NNT 36.
risk of ICU admission, 50.0% higher, RR 1.50, p = 1.00, treatment 3 of 36 (8.3%), control 2 of 36 (5.6%).
hospitalization time, 10.9% lower, relative time 0.89, p = 0.13, treatment 36, control 36.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sedighi et al., 20 Mar 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFluvoxamineAll
Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non‐critical COVID ‐19 pneumonia: A double‐blind randomized, placebo‐controlled clinical trial
Faranak Sedighi, Mehran Zarghami, Fatemeh Alizadeh arimi, Mahmood Moosazadeh, Shahram Ala, Roya Ghasemian, Hossein Mehravaran, Forouzan Elyasi
Neuropsychopharmacology Reports, doi:10.1002/npr2.12327
Introduction: Selective serotonin reuptake inhibitors are considered the drugs, whose effectiveness in viral pandemics has been studied. The aim of this study was to evaluate of adding fluoxetine to the treatment regimen of patients with COVID-19 pneumonia. Methods: This study was a double-blind randomized placebo controlled clinical trial .36 patients in the fluoxetine and 36 patients in the placebo group were enrolled. Patients in the intervention group were first treated with fluoxetine 10 mg for 4 days and then the dose of 20 mg was continued for 4 weeks. Data analysis was conducted using SPSS V. 22.0. Results: There was no statistically significant difference between the two groups in terms of clinical symptoms at the beginning of the study and also the score of anxiety and depression, oxygen saturation at the time of hospitalization, mid-hospitalization and discharge periods. The need for mechanical ventilator support (p = 1.00), the need for admission in the intensive care unit (ICU) (p = 1.00), rate for mortality (p = 1.00), and discharge with relative recovery (p = 1.00) were not significantly different between the two groups. The distribution of CRP within the study groups showed a significant decrease during different time periods (p = 0.001), and although there was no and at discharge (p = 0.585), mid-hospital CRP showed a significant decrease in the fluoxetine group (p = 0.032). Conclusion: Fluoxetine resulted in a faster reduction of patients' inflammation without association with depression and anxiety.
reported the side effects of fluoxetine and the evidence of reduced inflammatory processes was observed in the fluoxetine group. It is suggested that in future studies, the sample size would be calculated with the higher power to examine whether stronger findings can be achieved with larger sample size. Also the dose of the drug could be increased more rapidly and, if possible, increasing the dose to higher than 20 mg per day, can lead to greater efficacy of the drug. | CON CLUS ION ACK N OWLED G M ENTS The study was done with the financial support from the Vice Chancellor for Research of MAZUMS. We thank all those who helped us in this study. We also thank the patients for their cooperation in the fulfillment of this study and all hospital staff involved in patient treatment. FU N D I N G I N FO R M ATI O N This study was supported by the Mazandaran University of Medical Sciences. (Grant number = 8354). CO N FLI C T O F I NTER E S T S TATEM ENT The authors declare that they have no conflict of interest.
Ahmadi Livani, Gohardehi, Azizi, Hashemvarzi, Taghavi et al., Multisectoral actions of mental health during the COVID-19 pandemic in Mazandaran province of Iran, Neuropsychopharmacol Rep, doi:10.1002/npr2.12239
Azizi, Elyasi, Roodposhti, Bradycardia caused by interaction of venlafaxine and cyclosporine: a case report, Caspian J Intern Med
Baller, Hogan, Fusunyan, Ivkovic, Luccarelli et al., Neurocovid: pharmacological recommendations for delirium associated with COVID-19, Psychosomatics, doi:10.1016/Fj.psym.2020.05.013
Bishara, Kalafatis, Taylor, Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents, Ther Adv Psychopharmacol, doi:10.1177/F2045125320935306
Boland, Verduin, Ruiz, Antidepressants
Caiaffo, Oliveira, De Sá, Neto, Anti-inflammatory, antiapoptotic, and antioxidant activity of fluoxetine, Pharmacol Res Perspect, doi:10.1002/prp1002.1231
Carpinteiro, Edwards, Hoffmann, Kochs, Gripp et al., Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells, Cell Rep Med, doi:10.1002/prp1002.1231
Castro, Garcez, Silva, Patient care during the COVID-19 pandemic: do not leave delirium behind, Braz J Psychiatry, doi:10.1590/F1516-4446-2020-1048
Fda, Flouxetine, None
Gulbins, Palmada, Reichel, Lüth, Böhmer et al., Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs, Nat Med, doi:10.1038/nm.3214
Hiles, Baker, De Malmanche, Attia, Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis, Psychol Med, doi:10.1017/s0033291712000128
Hoertel, Rico, Vernet, Beeker, Jannot et al., Association between SSRI antidepressant use and reduced risk of intubation or death in hospitalized patients with coronavirus disease 2019: a multicenter retrospective observational study, doi:10.1038/s41380-41021-01021-41384
Kamali, Moosazadeh, Azizi, Ghasemian, Reskati et al., Anxiety due to COVID-19 among healthcare providers during pandemic: a web-based cross-sectional survey in Iran, Neuropsychopharmacol Rep, doi:10.1002/npr2.12213
Karimi-Khouzani, Heidarian, Amini, Anti-inflammatory and ameliorative effects of gallic acid on fluoxetine-induced oxidative stress and liver damage in rats, Pharmacol Rep, doi:10.1016/j.pharep.2017.1003.1011
Köhler, Freitas, Stubbs, Maes, Solmi et al., Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis, Mol Neurobiol, doi:10.1001/jama.2020.22760
Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2020.22760
Montazeri, Vahdaninia, Ebrahimi, Jarvandi, The hospital anxiety and depression scale (HADS): translation and validation study of the Iranian version, Health Qual Life Outcomes, doi:10.1186/1477-7525-1181-1114
Németh, Szûcs, Vitrai, Juhász, Németh et al., Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: a retrospective case-control study, Ideggyogy Sz, doi:10.18071/isz.18074.10389
Oskotsky, Marić, Tang, Oskotsky, Wong et al., Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial, Neuropsychopharmacol Rep
Reis, Moreira-Silva, Silva, Thabane, Milagres et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health, doi:10.1016/s2214-1109x(1021)00448-00444
Roumestan, Michel, Bichon, Portet, Detoc et al., Anti-inflammatory properties of desipramine and fluoxetine, Respir Res, doi:10.1186/1465-9921-1188-1135
Schloer, Brunotte, Goretzko, Mecate-Zambrano, Korthals et al., Targeting the endolysosomal host-SARS-CoV-2 interface by the clinically licensed antidepressant fluoxetine, Biorxiv, doi:10.1080/22221751.2020.1829082
Terauchi, Hiramitsu, Akiyoshi, Owa, Kato et al., Associations between anxiety, depression and insomnia in peri-and post-menopausal women, Maturitas, doi:10.1016/j.maturitas.2012.1001.1014
Williamson, Walker, Bhaskaran, Bacon, Bates et al., OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients, medRxiv, doi:10.1038/s41586-020-2521-4
Yang, Ding, Hu, Zhang, Sheng, Reliability and validity of a Chinese version of the HADS for screening depression and anxiety in psycho-cardiological outpatients, Compr Psychiatry, doi:10.1016/j.comppsych.2013.1008.1012
Zigmond, Snaith, The hospital anxiety and depression scale, Acta Psychiatr Scand, doi:10.1111/j.1600-0447.1983.tb09716.x
Zimniak, Kirschner, Hilpert, Geiger, Danov et al., The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2 in human lung tissue, Sci Rep, doi:10.1038/s41598-021-85049-0
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop